ethyl 1-(p-hydroxyphenyl)cyclopropane-2-acetate | 381226-88-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: ethyl 1-(p-hydroxyphenyl)cyclopropane-2-acetate
• 英文别名: ethyl 2-(2-(4-hydroxyphenyl)cyclopropyl)acetate；Ethyl [(+)-2-(4-hydroxyphenyl)cyclopropyl]acetate；ethyl 2-[2-(4-hydroxyphenyl)cyclopropyl]acetate
• CAS: 381226-88-6
• 化学式: C₁₃H₁₆O₃
• 分子量: 220.268
• InChiKey: KYHXXOJDWUUMIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 1-(p-hydroxyphenyl)cyclopropane-2-acetate 在 lithium hydroxide 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 20.0h， 生成 2-[4-[2-[6-(methylamino)-2-pyridinyl]ethoxy]phenyl]cyclopropaneacetic acid
  参考文献：
  名称：

  Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization

  摘要：

  The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.020
• 作为产物：
  描述：

  ethyl 1-(p-methoxyphenyl)cyclopropane-2-acetate 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以89%的产率得到ethyl 1-(p-hydroxyphenyl)cyclopropane-2-acetate
  参考文献：
  名称：

  Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

  摘要：

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。

  公开号：

  US20040092538A1

文献信息

• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR GPR120 ET LEURS UTILISATIONS
  申请人：METABOLEX INC

  公开号：WO2011159297A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• [EN] GPR120 RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DE RÉCEPTEURS GPR 120 ET LEURS APPLICATIONS
  申请人：METABOLEX INC

  公开号：WO2010080537A1

  公开（公告）日：2010-07-15

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  GPR120激动剂已提供。这些化合物对于治疗代谢性疾病，包括II型糖尿病和与血糖控制不佳有关的疾病非常有用。
• GPR120 RECEPTOR AGONISTS AND USES THEREOF
  申请人：Shi Dong Fang

  公开号：US20110313003A1

  公开（公告）日：2011-12-22

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  提供了GPR120激动剂。这些化合物对于治疗代谢性疾病非常有用，包括II型糖尿病和与血糖控制不佳有关的疾病。
• GPR120 receptor agonists and uses thereof
  申请人：Metabolex Inc.

  公开号：EP2514745A1

  公开（公告）日：2012-10-24

  GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

  提供了 GPR120 激动剂。这些化合物可用于治疗代谢性疾病，包括 II 型糖尿病和与血糖控制不良有关的疾病。
• US6921767B2
  申请人：——

  公开号：US6921767B2

  公开（公告）日：2005-07-26